Zuma 7 has OS benefit... Not so fast.
Kite has made an announcement. Zuma-7, a randomized control trial of axicel versus auto transplant, has achieved an OS benefit. Let's be clear on who's in this study. It's patients with DLBCL who are primary refractory or those who relapsed within 12 months. Relapse within 12 months is not the same as relapse at 24 months. Moreover, we all know there's …
Read more
2 years ago · 11 likes · 1 comment · Vinay Prasad